Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Not yet recruiting 3Recruiting 2Active not recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 40Magnetic Resonance Spectroscopy 28Carboplatin 19Gemcitabine 18Biopsy 17Cyclophosphamide 15fludarabine 14Paclitaxel 14Cisplatin 14pembrolizumab 13Oxaliplatin 12Dexamethasone 12Radiotherapy 11Injections 11Nivolumab 10Interviews as Topic 9venetoclax 8Irinotecan 8Fluorouracil 8Bevacizumab 8X-Rays 7Radiosurgery 7Drug Therapy 7Capecitabine 7Bortezomib 7cemiplimab 6Rituximab 6Pemetrexed 6Doxorubicin 6Calcium Dobesilate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Hyaluronoglucosaminidase × 30 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
336 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡